Literature DB >> 17628452

Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage.

Jørgen de Jonge1, Jean-Pierre Amorij, Wouter L J Hinrichs, Jan Wilschut, Anke Huckriede, Henderik W Frijlink.   

Abstract

Influenza virosomes are reconstituted influenza virus envelopes that may be used as vaccines or as carrier systems for cellular delivery of therapeutic molecules. Here we present a procedure to generate influenza virosomes as a stable dry-powder formulation by freeze-drying (lyophilization) using an amorphous inulin matrix as a stabilizer. In the presence of inulin the structural integrity and fusogenic activity of virosomes were fully preserved during freeze-drying. For example, the immunological properties of the virosomes, i.e. the HA potency in vitro and the immunogenic potential in vivo, were maintained during lyophilization in the presence of inulin. In addition, compared to virosomes dispersed in buffer, inulin-formulated virosomes showed substantially prolonged preservation of the HA potency upon storage. Also the capacity of virosomes to mediate cellular delivery of macromolecules was maintained during lyophilization in the presence of inulin and upon subsequent storage. Specifically, when dispersed in buffer, virosomes with encapsulated plasmid DNA lost their transfection activity completely within 6 weeks, whereas their transfection activity was fully preserved for at least 12 weeks after incorporation in an inulin matrix. Thus, in the presence of inulin as a stabilizing agent, the shelf-life of influenza virosomes with and without encapsulated macromolecules was considerably prolonged. Formulation of influenza virosomes as a dry-powder is advantageous for storage and transport and offers the possibility to develop needle-free dosage forms, e.g. for oral, nasal, pulmonal, or dermal delivery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17628452     DOI: 10.1016/j.ejps.2007.05.112

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  12 in total

1.  Formulation and stabilization of Francisella tularensis live vaccine strain.

Authors:  Satoshi Ohtake; Russell A Martin; Atul Saxena; David Lechuga-Ballesteros; Araceli E Santiago; Eileen M Barry; Vu Truong-Le
Journal:  J Pharm Sci       Date:  2011-04-13       Impact factor: 3.534

2.  Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Authors:  Min-Chul Kim; Jeong Woo Lee; Hyo-Jick Choi; Yu-Na Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Jong Seok Lee; Carlo Montemagno; Mark R Prausnitz; Sang-Moo Kang
Journal:  J Control Release       Date:  2015-05-21       Impact factor: 9.776

3.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

4.  Formulation of microneedles coated with influenza virus-like particle vaccine.

Authors:  Yeu-Chun Kim; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  AAPS PharmSciTech       Date:  2010-07-30       Impact factor: 3.246

5.  Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.

Authors:  Felix Geeraedts; Vinay Saluja; Wouter ter Veer; Jean-Pierre Amorij; Henderik W Frijlink; Jan Wilschut; Wouter L J Hinrichs; Anke Huckriede
Journal:  AAPS J       Date:  2010-03-02       Impact factor: 4.009

6.  Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.

Authors:  Yeu-Chun Kim; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  J Control Release       Date:  2009-10-17       Impact factor: 9.776

Review 7.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

8.  Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine.

Authors:  Peter C Soema; Sietske K Rosendahl Huber; Geert-Jan Willems; Wim Jiskoot; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  Pharm Res       Date:  2014-10-25       Impact factor: 4.200

9.  Solid bioneedle-delivered influenza vaccines are highly thermostable and induce both humoral and cellular immune responses.

Authors:  Peter C Soema; Geert-Jan Willems; Klaas van Twillert; Gijsbert van de Wijdeven; Claire J Boog; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

10.  Antioxidants keep the potentially probiotic but highly oxygen-sensitive human gut bacterium Faecalibacterium prausnitzii alive at ambient air.

Authors:  M Tanweer Khan; Jan Maarten van Dijl; Hermie J M Harmsen
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.